Initiation of the RESTORE registrational study in mid-2026 and biomechanical gait analysis results expected in Q2 2026 are key near-term catalysts. Monitor cash burn rate and potential need for financing as the company advances late-stage trials.
Price Chart
Executive Summary
NervGen reported Q1 2026 results with a net loss of $1.7M, improved from $3.9M a year ago due to non-cash warrant gains, and highlighted a successful FDA End-of-Phase 2 meeting aligning on parameters for the registrational RESTORE study of NVG-291 in chronic tetraplegia, on track for mid-2026 initiation. The regulatory milestone de-risks the path forward for the lead candidate, though the company remains pre-revenue with a cash runway of $16.6M.
Key Facts
- Completed successful FDA End-of-Phase 2 meeting, reaching alignment on RESTORE registrational study parameters for NVG-291 in chronic tetraplegia.
- RESTORE study on track for initiation in mid-2026 with site activation underway.
- Cash and investments of $16.6 million as of March 31, 2026.
- Net loss reduced to $1.7 million ($0.02 basic EPS) from $3.9 million in Q1 2025, mainly due to $5.7M non-cash unrealized gain on warrant derivative.
- R&D expenses increased to $4.9 million (vs $3.1 million) reflecting preparation for registrational study.
Financial Impact
Net loss of $1.7M improved from $3.9M, but primarily due to non-cash warrant gains; cash burn rate increased with R&D spend up 58% YoY.
Risk Factors
- Cash runway limited to $16.6M with increasing R&D expenses; likely need for additional financing.
- Clinical trial risks: enrollment, efficacy, and safety in RESTORE study.
- No approved products or revenue; valuation dependent on pipeline success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-063212 |
| Document: tm2614980d1_6k.htm | 0001104659-26-063212 |
| Document: 0001104659-26-063212-index-headers.html | 0001104659-26-063212 |
| Document: 0001104659-26-063212-index.html | 0001104659-26-063212 |
| Document: 0001104659-26-063212.txt | 0001104659-26-063212 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 6-K | $1.88 $1.81 | ▲ +3.72% | ▲ +4.93% | $1.48 (+21.28%) |
Sep 25, 2026 4w ago | Press Release | $1.88 $1.81 | ▼ −3.72% | ▼ −4.93% | $1.48 (−21.28%) |
Sep 24, 2026 4w ago | 6-K | $2.02 $1.76 | ▼ −12.87% | ▼ −12.46% | $1.48 (−26.73%) |
Aug 13, 2026 10w ago | 6-K | $1.76 $1.76 | · 0.00% | ▲ +1.96% | $1.48 (−15.91%) |
Aug 13, 2026 10w ago | Press Release | $1.76 $1.76 | · 0.00% | ▲ +1.96% | $1.48 (−15.91%) |
Jul 2, 2026 16w ago | 6-K | $2.12 $1.86 | ▲ +12.26% | ▲ +13.19% | $1.48 (+30.19%) |
Jun 1, 2026 21w ago | 6-K | $2.00 $1.81 | ▲ +9.50% | ▲ +6.54% | $1.48 (+26.00%) |
May 27, 2026 21w ago | EFFECT | $2.07 $1.91 | ▼ −7.73% | ▼ −8.20% | $1.48 (−28.50%) |
May 26, 2026 22w ago | 6-K | $2.07 $2.00 | ▼ −3.38% | ▼ −4.59% | $1.48 (−28.50%) |
May 22, 2026 22w ago | 6-K | $2.13 $2.00 | ▲ +6.10% | ▲ +7.32% | $1.48 (+30.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers